Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.
On 21 June 2004, orphan designation (EU/3/04/205) was granted by the European Commission to Stringer Consultancy Services Ltd, United Kingdom, for suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphoma.
The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in September 2004.
Suberolylanilide hydroxamic acid
Treatment of cutaneous T-cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Merck Sharp & Dohme Limited
Tel. +44 (0)1992 467272
Fax +44 (0)1992 479191
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: